| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Non-small cell lung cancer |
Mar 2023 |
Not Recommended |
| NETUPITANT WITH PALONOSETRON |
Akynzeo® |
Juniper Biologics Pty Ltd |
Nausea and vomiting |
Mar 2023 |
Recommended |
| ALIROCUMAB |
Praluent® |
Sanofi-Aventis Australia Pty Ltd |
Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia. |
Mar 2023 |
Recommended |
| DARATUMUMAB |
Darzalex® |
Janssen-Cilag Pty Ltd |
Multiple myeloma |
Mar 2023 |
Not Recommended |
| TICAGRELOR |
Brilinta® |
AstraZeneca Pty Ltd |
Acute coronary syndrome |
Mar 2023 |
Not Recommended |
| ANIFROLUMAB |
Saphnelo® |
AstraZeneca Pty Ltd |
Systemic lupus erythematosus |
Mar 2023 |
Not Recommended |
| HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL AND WITH HYDROXYPROPYL
GUAR |
Systane® Hydration |
Alcon Laboratories (Australia) Pty Ltd |
Severe dry eye syndrome |
Mar 2023 |
Deferred |
| BUDESONIDE |
Jorveza® |
Dr Falk Pharma Australia Pty Ltd |
Eosinophilic oesophagitis |
Mar 2023 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT PHENYLALANINE AND TYROSINE
AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
TYR explore5™ |
Vitaflo Australia Pty Limited |
Tyrosinaemia |
Mar 2023 |
Recommended |
| ENZALUTAMIDE |
Xtandi® |
Astellas Pharma Australia Pty Ltd |
Prostate cancer |
Mar 2023 |
Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
Tylactin RTD |
Cortex Health Pty Ltd |
Tyrosinaemia |
Mar 2023 |
Recommended |
| ZANUBRUTINIB |
Brukinsa® |
Beigene Aus Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic leukaemia |
Mar 2023 |
Recommended |
| URSODEOXYCHOLIC ACID |
Ursofalk® |
Dr Falk Pharma Australia Pty Ltd |
Primary biliary cholangitis |
Mar 2023 |
Recommended |
| DURVALUMAB |
Imfinzi® |
AstraZeneca Pty Ltd |
Biliary tract cancer |
Mar 2023 |
Not Recommended |
| FOSNETUPITANT (AS CHLORIDE HYDROCHLORIDE)/PALONOSETRON (AS HYDROCHLORIDE) |
Akynzeo®IV |
Juniper Biologics Pty Ltd |
Nausea and vomiting |
Mar 2023 |
Recommended |
| RIOCIGUAT |
Adempas® |
Bayer Australia Ltd |
Pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension |
Mar 2023 |
Not Applicable |
| ROMOSOZUMAB |
Evenity® |
Amgen Australia Pty Limited |
Osteoporosis |
Mar 2023 |
Recommended |
| TILDRAKIZUMAB |
Ilumya® |
Sun Pharma ANZ Pty Ltd |
Severe chronic plaque psoriasis |
Mar 2023 |
Not Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Breast cancer |
Mar 2023 |
Recommended |
| LAROTRECTINIB |
Vitrakvi® |
Bayer Australia Ltd |
Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions |
Mar 2023 |
Not Applicable |
| ABEMACICLIB |
Verzenio™ |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2023 |
Recommended |
| AMINO ACID SYNTHETIC FORMULA SUPPLEMENTED WITH LONG CHAIN POLYUNSATURATED FATTY ACIDS |
EleCare® LCP |
Abbott Australasia Pty Ltd |
Cows' milk protein enteropathy; Severe cows' milk protein enteropathy with failure
to thrive; Combined intolerance to cows' milk protein, soy protein and protein hydrolysate
formulae; Cows' milk anaphylaxis; Proven combined immunoglobulin E (IgE) mediated
allergy to cows' milk protein and soy protein; Severe intestinal malabsorption including
short bowel syndrome. |
Mar 2023 |
Recommended |
| HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND
CARBOHYDRATE |
- KetoVie 3:1
- KetoVie 4:1
- KetoVie Peptide 4:1
|
Cortex Health Pty Ltd |
Ketogenic diet |
Mar 2023 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT METHIONINE AND SUPPLEMENTED
WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
HCU explore5™ |
Vitaflo Australia Pty Limited |
Pyridoxine non-responsive homocystinuria |
Mar 2023 |
Recommended |
| BIMEKIZUMAB |
Bimzelx® |
UCB Australia Proprietary Limited |
Chronic plaque psoriasis |
Mar 2023 |
Recommended |
| CHLORMETHINE HYDROCHLORIDE |
Ledaga® |
Juniper Biologics Pty Ltd |
Mycosis fungoides-type cutanous T-cell lymphoma |
Mar 2023 |
Not Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Breast cancer |
Mar 2023 |
Not Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
- Camino Pro Bettermilk
- PKU Glytactin RTD 15
|
Cortex Health Pty Ltd |
Phenylketonuria |
Mar 2023 |
Recommended |
| FINERENONE |
Kerendia® |
Bayer Australia Ltd |
Chronic kidney disease in Type 2 diabetes |
Mar 2023 |
Recommended |
| UPADACITINIB |
Rinvoq® |
Abbvie Pty Ltd |
Crohn disease |
Mar 2023 |
Not Applicable |
| ZANUBRUTINIB |
Brukinsa® |
Beigene Aus Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic leukaemia |
Mar 2023 |
Recommended |
| DIFELIKEFALIN |
Korsuva® |
Vifor Pharma Pty Limited |
Chronic kidney disease associated pruritus |
Mar 2023 |
Not Recommended |
| INCLISIRAN |
Leqvio® |
Novartis Pharmaceuticals Australia Pty Limited |
Hypercholesterolaemia |
Mar 2023 |
Not Recommended |
| NIRAPARIB |
Zejula® |
GlaxoSmithKline Australia Pty Ltd |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Mar 2023 |
Deferred |
| MIFEPRISTONE AND MISOPROSTOL |
MS-2 Step® |
MS Health Pty Ltd |
Termination of an intrauterine pregnancy |
Mar 2023 |
Recommended |
| OLAPARIB |
Lynparza® |
AstraZeneca Pty Ltd |
Breast cancer |
Mar 2023 |
Not Recommended |
| RAVULIZUMAB |
Ultomiris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Atypical haemolytic uraemic syndrome |
Mar 2023 |
Deferred |
| TEBENTAFUSP |
Kimmtrak® |
Synevi Pty Limited |
Advanced (unresectable or metastatic) human leukocyte antigen (HLA)-A*02:01-positive
uveal melanoma |
Mar 2023 |
Not Recommended |
| RISDIPLAM |
Evrysdi® |
Roche Products Pty Ltd |
Spinal muscular atrophy |
Mar 2023 |
Recommended |
| TOFACITINIB |
Xeljanz® |
Pfizer Australia Pty Ltd |
Ankylosing spondylitis |
Mar 2023 |
Recommended |
| CARMELLOSE WITH GLYCERIN AND WITH HYALURONIC ACID |
Optive Fusion® |
Allergan Australia Pty Limited |
Severe dry eye syndrome |
Mar 2023 |
Deferred |
| APREMILAST |
Otezla® |
Amgen Australia Pty Limited |
Psoriatic arthritis |
Mar 2023 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma. |
Mar 2023 |
Not Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE
AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID |
MSUD explore5™ |
Vitaflo Australia Pty Limited |
Maple syrup urine disease |
Mar 2023 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Gastro-oesophageal cancers |
Mar 2023 |
Recommended |
| PEMETREXED |
Pemetrexed EVER Pharma |
Interpharma Pty Ltd |
Mesothelioma or non-small cell lung cancer |
Mar 2023 |
Recommended |
| OSILODROSTAT |
Isturisa® |
Recordati Rare Diseases Australia Pty. Ltd. |
Cushing syndrome |
Mar 2023 |
Not Recommended |
| NATALIZUMAB |
Tysabri® |
Biogen Australia Pty Ltd |
Relapsing-remitting multiple sclerosis |
Mar 2023 |
Recommended |
| RISPERIDONE |
Okedi® |
Maxx Pharma Pty Ltd |
Schizophrenia |
Mar 2023 |
Not Applicable |
| RELATLIMAB AND NIVOLUMAB |
Opdualag® |
Bristol-Myers Squibb Australia Pty Ltd |
Melanoma |
Mar 2023 |
Recommended |
| TOFACITINIB |
Xeljanz® |
Pfizer Australia Pty Ltd |
Juvenile idiopathic arthritis |
Mar 2023 |
Recommended |
| PATIROMER |
Veltassa® |
Vifor Pharma Pty Ltd |
Hyperkalaemia |
Mar 2023 |
Recommended |
| ENFORTUMAB VEDOTIN |
Padcev® |
Astellas Pharma Australia Pty Ltd |
Urothelial cancer |
Mar 2023 |
Recommended |
| UPADACITINIB |
Rinvoq® |
Abbvie Pty Ltd |
Non-radiographic axial spondyloarthritis |
Mar 2023 |
Recommended |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
AstraZeneca Pty Ltd |
Breast cancer |
Mar 2023 |
Recommended |
| RISEDRONIC ACID |
Actonel® EC |
Theramex Australia Pty Ltd |
Osteoporosis |
Mar 2023 |
Not Recommended |
| DEUCRAVACITINIB |
Sotyktu® |
Bristol-Myers Squibb Australia Pty Ltd |
Plaque psoriasis |
Mar 2023 |
Recommended |
| ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR |
Trikafta® |
Vertex Pharmaceuticals (Australia) Pty, Ltd |
Cystic fibrosis |
Mar 2023 |
Recommended |
| DOSTARLIMAB |
Jemperli® |
GlaxoSmithKline Australia Pty Ltd |
Endometrial cancer |
Mar 2023 |
Not Applicable |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Endometrial cancer |
Mar 2023 |
Not Applicable |